News|Articles|December 3, 2025
Accelerate Cell Line Development with GPEx® Lightning: Speed, Stability, and Industry-Leading Titers
Author(s)Catalent
Catalent’s GPEx® Lightning platform delivers stable, high-yield cell lines with unmatched speed—achieving titers up to 15g/L for mAbs and 11g/L for bispecifics. With 25-day pool generation and up to 12 weeks saved on development timelines, this offering sheet outlines key performance metrics and benefits that make GPEx® Lightning a game-changer for biologics developers.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Lilly Launches UK Trial of Weight-Loss Drug as US Price Drops
2
BirchBioMed’s Idiopathic Pulmonary Fibrosis Treatment Receives Orphan Drug Designation
3
Batch Certification for New Manufacturing Technologies: The Qualified Person Role in a Digital Environment
4
FDA Deploys Agentic AI Capabilities for Agency Staff
5
